Frailty and Quality of Life in Older Men With Prostate Cancer
Follows older men with prostate cancer to study frailty and how screening tools predict outcomes.
Plain-language title generated from the registry record
Registry title: Frailty in Older Adults With Prostate Cancer: a Prospective Cohort Study
Key facts
- Where
- Limerick, IrelandSee the site
Where in Ireland
- University Hospital LimerickLimerick, IrelandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Limerick
- Trial code
- NCT07605936
- Record updated
- 26 May 2026
- Original description
Prostate cancer is the most common solid tumour cancer amongst men in Ireland, with almost 4,000 new cases diagnosed annually and a median age at diagnosis of 67 years. The incidence of frailty amongst cancer patients is high. Among patients undergoing systemic anti-cancer therapy, frailty increases the risk of treatment related toxicity, hospitalisation, and death and is associated with a poorer quality of life.Read full original descriptionShow less
A Prospective Cohort Study to Assess Frailty, Healthcare Needs and Health Related Quality of Life in Patients With a Diagnosis of Prostate Cancer
Prostate cancer is the most common solid tumour cancer amongst men in Ireland, with almost 4,000 new cases diagnosed annually and a median age at diagnosis of 67 years. The incidence of frailty amongst cancer patients is high. Among patients undergoing systemic anti-cancer therapy, frailty increases the risk of treatment related toxicity, hospitalisation, and death and is associated with a poorer quality of life.
This study aims to describe the demographic, clinical and frailty characteristics of men living with prostate cancer in the Mid-West of Ireland. In addition, we will assess the predictive accuracy of three frailty screening tools currently used in Irish clinical practice,G8, CFS and PRISMA 7, for predicting poorer outcomes at baseline, 6 and 12 months.
Inclusion: adults aged ≥65 years with a diagnosis of prostate cancer.
Exclusion: Neither the patient nor the carer has sufficient proficiency in English sufficiently to complete consent or baseline assessment; Patients will be excluded if they present outside of research nurse (RN) operational hours( 8am and 5pm Monday - Friday); Patients who are acutely unwell and unable to answer the questionnaire will also be excluded.